U.S. FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in favour of the clinical benefit of the phase III POLARIX study of Polivy in combination with R-CHP for people with previously untreated ...

“Today’s committee decision to recognize the potential of this Polivy combination as a first-line treatment option is important since four in 10 people with diffuse large B-cell lymphoma relapse or do ...

BOULDER, Colo., July 09, 2025 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (NASDAQ: AUUDW) (“Auddia” or the “Company”), today announced that Jeff Thramann has succeeded Michael Lawless as CEO of ...

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma - Columvi is the first bispecific antibody to ...

– U.S. FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in favor of the clinical benefit of the Phase III POLARIX study of Polivy in combination with R-CHP for people with previously untreated ...

There is "no therapeutic justification" for 14 fixed dose combination medications, including Nimesulide and Paracetamol dispersible tablets and Chlopheniramine Maleate and Codeine syrup, which the ...

GSK plc announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Blenrep for the treatment of adults with relapsed or ...

Recommendation to Advance to Increased Dose in Third and Final Cohort of Phase 1 Portion of Trial Indicates Favorable Safety Profile of Novel Gene Therapy in Solid Tumor Cancer AUSTIN, Texas, Dec. 14, ...

New independent board members with experience in AI infrastructure and the evaluation of entrepreneurial ventures added to form a special committee Special committee to evaluate merits of ...

Please provide your email address to receive an email when new articles are posted on . The FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 for approval of the novel combination ...